Latest Breaking News On - Pedram hamrah - Page 1 : vimarsana.com

Eversight Awards 2024 Eye & Vision Research Grants

Eversight Awards 2024 Eye & Vision Research Grants
invisionmag.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from invisionmag.com Daily Mail and Mail on Sunday newspapers.

Wayne-state-university
Michigan
United-states
Pedram-hamrah
Onkarb-sawant
Ashok-kumar
Jason-miller
Lev-prasov
Charlesi-thomas
Research-development
Cellular-biology-program
Department-of-ophthalmology

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

London
City-of
United-kingdom
Paul-spencer
Stefan-klotter
Garys-jacob
Pedram-hamrah
Pharma-limited
Cornea-service
Drug-administration
Business-development-investor-relations
National-organization-for-rare-disorders

OKYO Pharma shares surge on FDA clearance of Phase 2 neuropathic corneal pain trial

OKYO Pharma shares surge on FDA clearance of Phase 2 neuropathic corneal pain trial
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

New-york
United-states
Garys-jacob
Pedram-hamrah
Tufts-medical-center-as-principal-investigator
Okyo-pharma-ltd
Drug-administration
Nasdaq
Investigational-new-drug
Advisory-board
Tufts-medical-center

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved ...

London
City-of
United-kingdom
Garys-jacob
Pedram-hamrah
Translational-ocular-immunology-at-tufts-medical-center
Nasdaq
National-organization-for-rare-disorders
Drug-administration
Pharma-limited
Company-phase
Tufts-medical-center

OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board

OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

San-francisco
California
United-states
West-haven
Miami
Florida
London
City-of
United-kingdom
New-york
Mark-milner
Paul-spencer

OKYO Pharma appoints leading ophthalmologists to Scientific Advisory Board

OKYO Pharma appoints leading ophthalmologists to Scientific Advisory Board
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

Miami
Florida
United-states
Pedram-hamrah
Garys-jacob
Victor-perez
Mark-milner
Jay-pepose
University-of-miami-miller-school-medicine
Okyo-pharma-ltd
Bascom-palmer-eye-institute
Miami-va-medical-center

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (NCP)

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (NCP)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

London
City-of
United-kingdom
Garys-jacob
Pedram-hamrah
Paul-spencer
Translational-ocular-immunology-at-tufts-medical-center
Tufts-medical-center
Drug-administration
Company-phase
Pharma-limited
Cornea-service

OKYO Pharma files IND application OK-101 to treat Neuropathic Corneal Pain

OKYO Pharma Ltd (NASDAQ:OKYO), the clinical-stage drug developer, told investors it has filed an Investigational New Drug (IND) application with the US Food...

Pedram-hamrah
Gary-jacob
Tufts-medical-center
Drug-administration
Okyo-pharma-ltd
Cornea-service
Translational-ocular-immunology-at-tufts-medical-center
Investigational-new-drug
Neuropathic-corneal-pain
Academic-programs
Translational-ocular-immunology
Tufts-medical

Okyo reaches clinical trial agreement with Tufts

Okyo reaches clinical trial agreement with Tufts
pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.

Pedram-hamrah
Gary-jacob
Okyo-pharma
Tufts-medical-center
Pharma-limited
Tufts-medical

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (NCP) Following Announcement of Clinical Trial Agreement with Tufts Medical Center

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (NCP) Following Announcement of Clinical Trial Agreement with Tufts Medical Center
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

London
City-of
United-kingdom
Paul-spencer
Garys-jacob
Pedram-hamrah
Tufts-medical-center
Translational-ocular-immunology-at-tufts-medical-center
Cornea-service
Pharma-limited-nasdaq
Principal-investigator
Investigational-new-drug